Torrent Pharmaceuticals Limited announced the allotment of Senior, Secured, Redeemable, Listed, Rated, Non-Convertible Debentures (NCDs) on January 19, 2026.

The Securities Transfer and Stakeholders Relationship Committee approved the allotment of Series 1 Debentures, comprising 2,00,000 NCDs with a nominal value of ₹100,000 each, aggregating to ₹20,000,000,000 (2000 crore). These debentures carry a coupon rate of 7.45% per annum and have a tenure of 2 years, maturing on January 19, 2028.

Series 2 Debentures, numbering 2,49,000 NCDs of ₹100,000 each, aggregate to ₹24,900,000,000 (2490 crore). These have a coupon rate of 7.60% per annum and a tenure of 3 years, maturing on January 19, 2029.

Series 3 Debentures consist of 3,00,000 NCDs of ₹100,000 each, aggregating to ₹30,000,000,000 (3000 crore). These carry a coupon rate of 7.70% per annum and have a tenure of 3 years, 11 months, and 30 days, maturing on January 18, 2030.

Series 4 Debentures comprise 3,50,000 NCDs of ₹100,000 each, aggregating to ₹35,000,000,000 (3500 crore). These NCDs have a coupon rate of 7.80% per annum and a tenure of 4 years, 11 months, and 29 days, maturing on January 17, 2031.

All NCDs are listed on the Wholesale Debt Market Segment of the National Stock Exchange of India Limited and will be redeemed at par. The issuance was done through private placement. The company has created a first-ranking exclusive charge over a designated account for NCD proceeds and specified trademarks to provide a minimum security cover of 1.1x.